Northern Trust Corp Has $11.54 Million Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Northern Trust Corp lifted its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 11.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,199,970 shares of the company's stock after acquiring an additional 123,205 shares during the quarter. Northern Trust Corp owned about 0.82% of MiMedx Group worth $11,544,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in MDXG. IMG Wealth Management Inc. bought a new stake in MiMedx Group during the fourth quarter worth approximately $28,000. Van ECK Associates Corp acquired a new position in MiMedx Group in the 4th quarter worth approximately $40,000. Tower Research Capital LLC TRC boosted its stake in MiMedx Group by 77.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after purchasing an additional 2,837 shares during the period. AlphaQuest LLC acquired a new position in MiMedx Group in the 4th quarter worth approximately $88,000. Finally, Savant Capital LLC acquired a new position in MiMedx Group in the 4th quarter worth approximately $100,000. Institutional investors and hedge funds own 79.15% of the company's stock.

Insider Buying and Selling at MiMedx Group

In related news, CEO Joseph H. Capper bought 200,000 shares of the company's stock in a transaction on Friday, May 2nd. The stock was bought at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the purchase, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. The trade was a 60.69% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. This represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 144,018 shares of company stock worth $1,130,312 over the last ninety days. Corporate insiders own 1.70% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on MDXG. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th. Wall Street Zen downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday, May 9th.

MiMedx Group Stock Down 2.6%

Shares of MiMedx Group stock traded down $0.18 during midday trading on Thursday, reaching $6.72. 434,513 shares of the company's stock traded hands, compared to its average volume of 695,156. The company has a market cap of $992.56 million, a price-to-earnings ratio of 12.22 and a beta of 1.85. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The company's 50 day simple moving average is $7.11 and its 200 day simple moving average is $8.17.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. The company had revenue of $88.21 million for the quarter, compared to the consensus estimate of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Equities analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.